Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
May 07, 2024 08:00 ET
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024.
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
May 18, 2020 07:15 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 11, 2020 16:01 ET
|
Liquidia Technologies, Inc.
Received FDA Acceptance of LIQ861 NDA for ReviewReported Final Safety and Tolerability Results for LIQ861 Inspire TrialManagement to Host Webcast and Conference Call Today at 4:30p.m. ET ...
Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
January 07, 2019 07:00 ET
|
Liquidia Technologies, Inc.
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
Liquidia Technologies Provides Leadership Update
November 27, 2018 16:45 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO
November 14, 2018 16:30 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting
November 14, 2018 08:00 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Technologies to Present at Jefferies London Healthcare Conference
November 09, 2018 08:00 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
October 31, 2018 07:00 ET
|
Liquidia Technologies, Inc.
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...
Liquidia Technologies to Provide Third Quarter 2018 Corporate Update on October 31, 2018
October 23, 2018 08:00 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development...